JAK Inhibitors in 2019
Role in the therapeutic strategy in 2019
• RA: 2nd line after failure of conventional DMARDs
• PsoArth: after failure of NSAID, cDMARDs and/or biologics
• Ulcerative colitis: 3rd line after failure of 5-ASA, GCs, cDMARDS and anti-TNF-apha
Efficacy (Rheumatoid Arthritis, Psoriatic Arthritis)
• Superior to methotrexate
• Noninferior to combination of methotrexate + anti-TNFapha
• Efficacy as early as 3 weeks
• Maximum efficacy at 3 mo.
By Romain Muller via Dr. Benjamin Terrier @TerrierBen
#JAKInhibitors #Indications #Rheumatology #Management